Pancreatic Cancer Research

ResearcherShizuoka Cancer CenterNo recent work listed

Hiromichi Shirasu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7952-5528; OpenAlex author ID A5027703501. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper

Papers 2

  1. Effectiveness and safety of gemcitabine plus nab-paclitaxel in elderly patients with advanced pancreatic cancer: a single-center retrospective cohort study. Co-author DOI 10.1007/s10637-022-01221-x↗
  2. Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX. Co-author DOI 10.1111/cas.13883↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Akiko Todaka · 2 shared papers, 2019–2022 · strength 0.22
  2. Sae Ohwada · 1 shared paper, 2022 · strength 0.15
  3. Kentaro Yamazaki · 1 shared paper, 2022 · strength 0.15
  4. Takeshi Kawakami · 1 shared paper, 2022 · strength 0.15
  5. Hirofumi Yasui · 1 shared paper, 2022 · strength 0.15
  6. Hiroshi Nakase · 1 shared paper, 2022 · strength 0.15
  7. Akira Fukutomi · 1 shared paper, 2019 · strength 0.08
  8. Kentaro Sudo · 1 shared paper, 2019 · strength 0.08
  9. Hirofumi Fujii · 1 shared paper, 2019 · strength 0.08
  10. Keiko Kamei · 1 shared paper, 2019 · strength 0.08
  11. Nobumasa Mizuno · 1 shared paper, 2019 · strength 0.08
  12. Satoshi Kobayashi · 1 shared paper, 2019 · strength 0.08
  13. Naohiro Okano · 1 shared paper, 2019 · strength 0.08
  14. Hideyuki Hayashi · 1 shared paper, 2019 · strength 0.08
  15. Masato Ozaka · 1 shared paper, 2019 · strength 0.08
  16. Noritoshi Kobayashi · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.